Showing results (111-120 of 280) with videos related to

Sort By:
Pageof 28
Frontiers in Medicine|January 9, 2023
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancerJoe M O'Sullivan, Rana R McKay, Kambiz Rahbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2019
Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer DisparitiesTimothy J Robinson, Jennifer A Freedman, Muthana Al Abo, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
Urologic Oncology|September 17, 2019
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
Prostate Cancer and Prostatic Diseases|March 28, 2024
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerDaniel J George, Krishnan Ramaswamy, Hongbo Yang, et al.
The Prostate|May 3, 2019
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancerMegan Ann McNamara, Taofik Oyekunle, Bennett B Chin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC TrialAnup Patel, Alain Ravaud, Robert J Motzer, et al.
Urologic Oncology|January 28, 2017
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancerSundhar Ramalingam, Michael S Humeniuk, Rachel Hu, et al.
Future Oncology (London, England)|October 8, 2020
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer settingAnup Patel, Alain Ravaud, Robert J Motzer, et al.
The Oncologist|October 25, 2024
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT studyTomasz M Beer, Daniel J George, Neal D Shore, et al.
Pageof 28